Drug intelligence / Profile preview

STE

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

"STE" is an experimental oral nicotine product developed by McNeil AB. It is being investigated as a nicotine replacement therapy (NRT) and is undergoing bioequivalence studies against existing NRT products like Nicorette® Microtab. As an NRT, its primary function is to deliver nicotine to reduce withdrawal symptoms and cravings associated with nicotine dependence.

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on STE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STE.

Explore the full profile